Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peplin
With
TKL Research, Inc.
A 12 month long-term follow-up study of patients who have achieved complete clearance of AK lesions at the Day 57 in the Phase 3 studies PEP005-016 or PEP005-025.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must have achieved complete clearance of AK lesions (lesion count = 0) at Day 57 in one of the following Peplin AK clinical studies: PEP005-016 or PEP005-025
Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures
You may not be if
Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)
Early termination from study PEP005-016 or PEP005-025
Clareo Health | A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
